Table 1.
Examples of mouse models used to evaluate the anti-tumor efficacy of IgE molecules
| IgE species | IgE specificity | Targeted cancer cells | Mouse model | Refs |
|---|---|---|---|---|
| Murine | gp36 of MMTV | H2712 murine mammary carcinoma (s.c. and i.p.) | C3H/HeJ | [29] |
| Rat/human chimeric | Murine Ly-2 | E3 murine thymoma (s.c.) | C57BL/6 | [30] |
| Murine | DNP | MC38 murine colon carcinoma cells expressing human CEA (s.c.)a | C57BL/6 | [35] |
| Murine | DNP | TS/A-LACK murine mammary carcinoma cells coated with DNP (s.c.) | BALB/c | [36] |
| Murine and murine/human chimeric | Colorectal cancer antigen | Human COLO 205 (s.c.) | SCID | [39] |
| Rat/human chimeric | Murine Ly-2 | E3 murine thymoma (i.p.) | NOD-SCID | [41] |
| Mouse/human chimeric | FBP | IGROV-1 human ovarian carcinoma cells (s.c.) | C.B-17 scid/scid | [43] |
| HUA patient-derived ovarian carcinoma (i.p.) | nu/nu | [44–46] | ||
| Mouse/human chimeric | NIP | TS/A-LACK murine mammary carcinoma cells coated with NIP (s.c.) | Human FcεRIα transgenic BALB/c | [36] |
| Human | HER2/neu | D2F2/E2 murine mammary carcinoma cells expressing human HER2/neu (i.p.) | Human FcεRIα transgenic BALB/c | [57] |
s.c. Subcutaneous, i.p. intraperitoneal, MMTV murine mammary tumor virus, DNP dinitrophenol, FBP folate binding protein, NIP 4-hydroxy-5-iodo-3-nitrophenylacetyl
aTumor targeting occurred via a biotinylated anti-CEA IgG followed by streptavidin and then a biotinylated IgE